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Abstract 
Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur almost anywhere in the 
body. Their rarity, and the heterogeneity of subtype and location means that developing evidence-based guidelines 
is complicated by the limitations of the data available. However, this makes it more important that STS are managed 
by teams, expert in such cases, to ensure consistent and optimal treatment, as well as recruitment to clinical trials, and 
the ongoing accumulation of further data and knowledge. The development of appropriate guidance, by an expe-
rienced panel referring to the evidence available, is therefore a useful foundation on which to build progress in the 
field. These guidelines are an update of the previous version published in 2010 (Grimer et al. in Sarcoma 2010:506182, 
2010). The original guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened 
under the auspices of the British Sarcoma Group (BSG) and were intended to provide a framework for the multidisci-
plinary care of patients with soft tissue sarcomas. This current version has been updated and amended with reference 
to other European and US guidance. There are specific recommendations for the management of selected subtypes 
of disease including retroperitoneal and uterine sarcomas, as well as aggressive fibromatosis (desmoid tumours) and 
other borderline tumours commonly managed by sarcoma services. An important aim in sarcoma management is 
early diagnosis and prompt referral. In the UK, any patient with a suspected soft tissue sarcoma should be referred 
to  one of the specialist regional soft tissues sarcoma services, to be managed by a specialist sarcoma multidiscipli-
nary team. Once the diagnosis has been confirmed using appropriate imaging, plus a biopsy, the main modality of 
management is usually surgical excision performed by a specialist surgeon. In tumours at higher risk of recurrence 
or metastasis pre- or post-operative radiotherapy should be considered. Systemic anti-cancer therapy (SACT) may 
be utilized in some cases where the histological subtype is considered more sensitive to systemic treatment. Regu-
lar follow-up is recommended to assess local control, development of metastatic disease, and any late-effects of 
treatment. For local recurrence, and more rarely in selected cases of metastatic disease, surgical resection would be 
considered. Treatment for metastases may include radiotherapy, or systemic therapy guided by the sarcoma subtype. 
In some cases, symptom control and palliative care support alone will be appropriate.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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Background
Rationale and objective of guidelines
Soft tissue sarcomas (STS) are a relatively uncommon 
group of malignancies. On average a general practitioner 
may only see one sarcoma in their career. To improve 
diagnosis and treatment of these tumours, management 
was rationalized to peer-reviewed regional soft-tissue 
sarcoma services, and a smaller number of specialist 
units which also treat primary bone tumours [1]. An out-
line of best practice was set out in the National Institute 
for Health and Clinical Excellence Improving Outcomes 
Guidance for people with sarcoma (NICE-IOG) [2] pub-
lished in 2006.
These guidelines are an attempt to review current evi-
dence concerning soft-tissue sarcoma diagnosis and 
treatment, and provide recommendations to support best 
practice. They are not intended to be prescriptive, but 
aim to improve the quality of care for patients with STS 
by helping identify and inform the key decisions involved 
in their management. They will hopefully provide a 
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useful resource for sarcoma services to help guide mul-
tidisciplinary team (MDT) case discussions, and patient 
management.
Methods
This updated guideline has been authored and reviewed 
by specialists from the UK involved in diagnosing and 
treating patients with sarcoma. They include members 
of the British Sarcoma Group (BSG), and NHS England 
Sarcoma Clinical Reference Group (CRG). As with the 
previous version, current NICE, NCCN (National Com-
prehensive Cancer Network, US), and ESMO (European 
Society for Medical Oncology) guidance were referenced, 
tailoring the recommendations for UK practice. It pro-
vides a brief review of the current state of established 
knowledge in sarcoma diagnosis and management, with 
guidance on what is considered current best practice 
in the UK. It has been derived by a consensus of expert 
opinion based on their interpretation of currently avail-
able data, and their own clinical experience.
Scope of guidelines
These recommendations apply principally to soft tis-
sue sarcomas arising from limbs and trunk and although, 
where appropriate, specific guidance is given according to 
histological subtype it is recognised that some tumours, 
for example, Ewing sarcoma, and embryonal and alveolar 
rhabdomyosarcoma, require a different approach to man-
agement, and are excluded from this guidance [3]. These 
rare subtypes are relatively more common in paediatric 
and young adult patients. Ewing sarcoma arising in soft tis-
sue are managed in accordance with guidelines for Ewing 
sarcoma of bone (see UK bone sarcoma guidelines [4]). 
Rhabdomyosarcoma is the commonest sarcoma in chil-
dren and appropriately managed by children’s cancer mul-
tidisciplinary teams (MDTs), often within international 
clinical trials such as EpSSG RMS 2005 [5, 6] which include 
comprehensive treatment guidance. For other histologies 
arising in children and young people (often referred to as 
non-rhabdomyosarcoma, soft tissue sarcomas, NRSTS) 
much less evidence exists for optimal management, in par-
ticular the application of chemotherapy and radiotherapy. 
Close working between children’s cancer MDTs and sar-
coma MDTs should be regarded as best practice.
Specific recommendations on the management of ret-
roperitoneal and uterine sarcomas, as well as aggressive 
fibromatosis (desmoid tumours), plus some other condi-
tions referred commonly to sarcoma MDTs, are included 
separately within this guideline. Bone sarcomas and gas-
trointestinal stromal tumours (GISTs) are subject to their 
own specific BSG guidelines. The latest bone sarcoma 
guidelines have recently been published [4] and the GIST 
guidelines are currently being updated.
These guidelines focus on clinical effectiveness, giving a 
picture of what treatments a specialist sarcoma multidisci-
plinary team should have access to within the UK, subject 
to some flexibility to allow for evolving practice, but they 
do not employ the same detailed analysis of cost effective-
ness as NICE. In rare situations, treatment options may be 
suggested where NHS funding is not established. Unfortu-
nately, with rare tumours such as sarcoma, NICE, and the 
Cancer Drugs Fund (CDF), may be less likely to evaluate 
potential treatments. These guidelines can be considered 
to represent a broad consensus in 2016. They will require 
updating as knowledge and treatment evolve.
Specialised soft‑tissue sarcoma services
Following the publication of the National Institute for 
Health and Clinical Excellence Improving Outcomes 
Guidance for people with sarcoma (NICE-IOG) [2] in 
2006, the services for patients with sarcoma in England 
and Wales were centralised. There are currently five cen-
tres providing both bone and soft-tissue sarcoma services, 
and an additional ten centres who diagnose and treat only 
soft-tissue sarcoma, passing on referrals of suspected bone 
sarcomas to their regional bone sarcoma centre [7] and 
collaborating on aspects of management. In England, ser-
vices are commissioned and delivered in accordance with 
the current NHS England service specification [8]. In Scot-
land, the Scottish Sarcoma Network coordinates care of 
patients at five centres, and in Northern Ireland all bone 
sarcomas are managed at Musgrave Park Hospital with 
soft-tissue sarcomas also seen at four other centres.
Each specialist service must have a multidisciplinary 
team (MDT) made up of radiologists, surgeons, medical 
and clinical oncologists, pathologists, specialist nurses, 
and an MDT co-ordinator. The surgical team will include 
specialist plastic, general, or orthopaedic surgeons, with 
an extended team available, which may include retroperi-
toneal, thoracic, vascular, and other surgical disciplines, 
plus allied health professionals such as physiotherapists 
and occupational therapists. Supportive and palliative 
care services also contribute. The MDT will hold weekly 
meetings to discuss new suspected, and proven cases of 
sarcoma. The MDT meeting outcomes should be pro-
vided promptly to referring clinicians.
Epidemiology
Sarcomas are relatively uncommon tumours accounting 
for approximately 1% of all adult cancers [9]. They consti-
tute a heterogeneous group of tumours of mesenchymal 
cell origin, often with a distinct age distribution, site of 
presentation, natural biological behaviour and prognosis. 
There are more than 50 subtypes divided into two broad 
categories: soft tissue sarcomas and sarcomas of bone 
[10].
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Historically, because of the heterogeneity of this group 
of tumours, the true incidence has generally been under-
reported. In 2010 around 3300 people were diagnosed 
with soft tissue sarcoma in the UK, with around 90 cases 
in children under 15. In the Teenage and Young Adult 
(TYA) age range (17–25  years) around 80 cases were 
recorded [11]. The National Cancer Intelligence Network 
(NCIN) reports that the incidence of STS is approxi-
mately 45/million population per year (NCIN) [12]. Bone 
sarcomas are rarer with an incidence around a fifth that 
of STS; 559 new cases were recorded in 2011 [11]. How-
ever, they represent a significant proportion of the cancer 
burden in young people under the age of 20 years.
Soft tissue sarcomas may occur at any age, most often in 
middle aged and older adults; however, as a proportion of 
paediatric malignancies they are relatively common com-
prising 7–10% of all childhood cancers. They are an impor-
tant cause of death in the 14–29 years’ age group [13–16].
Approximately half of all STS patients with interme-
diate or high-grade tumours develop metastatic disease 
requiring systemic treatment [17]; the overall survival is 
approximately 55% at 5 years [12, 18].
Aetiology
For the vast majority of cases, the aetiology is unknown, 
although there are certain genetic associations, such 
as the 10% lifetime risk of malignant peripheral nerve 
sheath tumour (MPNST) in individuals with familial neu-
rofibromatosis, caused by mutations in the NF1 gene [19, 
20]. There is an increased risk of sarcomas, both bone 
and soft tissue, in patients who have had a familial retino-
blastoma, caused by inherited mutations in the RB gene 
[21]. Similarly, there is an increased risk of sarcomas, and 
other cancers in families with Li-Fraumeni syndrome 
who have inherited mutations in the TP53 tumour sup-
pressor gene [22]. There is also a small risk of sarcoma in 
areas of the body previously treated using radiotherapy, 
for example angiosarcoma following treatment for breast 
cancer.
Clinical presentation
Due to the heterogeneous sites of origin of STS, it is dif-
ficult to clearly define the clinical features of the disease. 
However, a soft tissue lump exhibiting any of the follow-
ing three clinical features should be considered to be 
malignant until proved otherwise [23]:
1. Increasing in size.
2. Size more than 5 cm.
3. Painful.
The more of these clinical features present, the greater 
the risk of malignancy with increasing size being the best 
individual indicator. In addition, deeper lying masses are 
more likely to be sarcomas.
Soft tissue masses are not uncommon and most will 
turn out to be benign, often lipomata. NICE produced 
updated guidelines in 2015, aimed at primary care, for 
early diagnosis of soft tissue sarcomas [24]. They suggest 
that the criteria for urgent referral should be adhered to 
even if the risk of malignancy is only 3%.
  • Consider an urgent direct access ultrasound scan (to 
be performed within 2 weeks) to assess for soft tissue 
sarcoma in adults with an unexplained lump that is 
increasing in size.
  • Consider a suspected cancer pathway referral (for an 
appointment within 2 weeks) for adults if they have 
ultrasound findings that are suggestive of soft tissue 
sarcoma or if ultrasound findings are uncertain and 
clinical concern persists.
If there is a particularly high suspicion of malignancy, 
and requesting an ultrasound in the primary care setting 
might introduce delay, then direct urgent referral to the 
regional sarcoma service should be considered. Regional 
services should provide referral advice on their websites 
or urgent referral forms. Any lesions previously thought 
to be benign that increase in size or develop other suspi-
cious features should be considered for further investiga-
tion. Other diagnoses to consider in the case of palpable 
masses include metastases and lymphoma.
Any retroperitoneal or intra-abdominal mass with 
imaging appearances suggestive of a soft tissue sarcoma 
should be referred to a specialist centre before biopsy or 
surgical treatment.
Key recommendations
1. Any patient with a soft tissue mass that is increasing 
in size, or has a size more than 5 cm, whether or not 
it is painful, should either be referred for an urgent 
ultrasound scan, or referred directly to a sarcoma 
diagnostic centre.
2. If the ultrasound scan does not confidently confirm a 
benign diagnosis, then the patient should be referred 
for further investigation on an urgent suspected can-
cer pathway referral.
3. Any retroperitoneal or intra-abdominal mass with 
imaging appearances suggestive of a soft tissue sar-
coma should be referred to a specialist centre before 
biopsy or surgical treatment.
Referral and assessment
Regional diagnostic services
The regional sarcoma services should support the devel-
opment of efficient pathways for the investigation of 
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suspected sarcomas. This may include providing infor-
mation to local primary care or radiology services on the 
initial investigation and onward referral of patients with 
soft-tissue masses, and effective pathways to make direct 
suspected-cancer referrals when required.
Carcinosarcomas are generally viewed as epithe-
lial tumours exhibiting sarcomatous differentiation. 
Although new biological insights are emerging [25], cur-
rently management would usually be as for epithelial 
tumours, and guided by the relevant cancer MDT.
Imaging
Diagnostic
Any patient with a suspected STS should be referred for 
an initial ultrasound scan, or direct to a diagnostic cen-
tre for triple assessment with clinical history, imaging, 
and biopsy [24]. An initial ultrasound is often useful in 
lower-risk cases to confirm benign conditions such as 
simple lipomata. In the hands of a non musculo-skeletal 
ultrasonographer however errors may arise and so there 
should be a low threshold for referral for further investi-
gation. A more definitive ultrasound may be performed 
by a musculoskeletal radiologist who ideally is a mem-
ber of the sarcoma MDT. Any patients with suspicious 
ultrasound or clinical features should usually have an 
MRI scan of the region affected. Plain X-ray may be used 
to identify bone involvement and risk of fracture, or to 
detect calcification. For retroperitoneal tumours CT is 
often more convenient, and as useful as MRI.
Staging
Patients with a confirmed STS should be staged with 
a CT chest to exclude pulmonary metastases prior to 
definitive treatment, although plain chest X-ray may be 
acceptable in a minority of cases (e.g. the frail elderly and 
those with small, low grade lesions). In most cases CT 
abdomen/pelvis and isotope bone scan are not routine 
staging investigations, but CT may be considered, par-
ticularly in lower extremity tumours [26]. Depending on 
the histological type and other clinical features [26], fur-
ther staging assessments may be advised as below:
  • CT or MRI scan for regional lymph node assessment 
for synovial sarcoma, clear cell sarcoma, or epithe-
lioid sarcoma due to a higher risk of nodal involve-
ment.
  • Atypical lipomatous tumours (ALT) of the extremi-
ties have a very low risk of metastatic spread and so 
chest X-ray may be considered adequate staging (see 
“Lipomas and atypical lipomatous tumours” section).
  • In cases of myxoid liposarcoma soft-tissue metas-
tases are more common and so abdominal and pel-
vic CT scan should be performed. Alternatively, 
although not yet established as routine practice, 
whole-body MRI has been shown to have potential 
utility in identifying occult metastatic disease and 
can be considered [27].
  • Brain CT or MRI can be considered in cases of alveo-
lar soft part sarcoma and clear cell sarcoma due to a 
higher incidence of brain metastases [28].
  • Positron emission tomography (PET-CT) scanning is 
not yet proven as a routine investigation in sarcoma 
although may be considered before performing radi-
cal surgery, such as amputation for primary or recur-
rent disease [29]. It also provides a single investiga-
tion which can replace a separate CT and bone scan, 
and is being applied more commonly in sarcomas of 
younger patients such as Ewing sarcoma and rhabdo-
myosarcoma [30, 31]. Although some work has been 
done assessing tumour response to systemic treat-
ment using PET; this is currently still investigational. 
PET-CT might have some utility in diagnosing neu-
rofibromatosis 1 (NF1) associated malignant periph-
eral nerve sheath tumours (MPNST) [32, 33].
Biopsy
The standard approach to diagnosis of a suspicious mass is 
percutaneous core needle biopsy—several cores should be 
taken to maximise diagnostic yield. However, an incisional 
biopsy may be necessary on rare occasions, and excision 
biopsy may be the most practical option for small superfi-
cial lesions (<2 cm diameter). Biopsies of large lipomatous 
lesions with concerning features, should aim to sample areas 
appearing more heterogeneous on imaging, and need to be 
interpreted with caution as areas of dedifferentiation may 
be missed. The biopsy should be planned in such a way that 
the biopsy tract can be safely removed at the time of defini-
tive surgery to reduce the risk of seeding, and should be 
performed at a diagnostic clinic by, or in conjunction with, 
a specialist radiologist or sarcoma surgeon. Fine needle aspi-
ration (FNA) is not recommended as a primary diagnostic 
modality, although it may be considered for confirming dis-
ease recurrence, or nodal metastases.
Histology—diagnosis
Histological diagnosis should be made according to the 
2013 WHO Classification [10] to determine the grade 
and stage of the tumour. The grade should be provided in 
all cases where possible based on a recognised system. In 
Europe, the Fédération Nationale des Centres de Lutte Con-
tre le Cancer (FNCLCC) grading system is generally used, 
which distinguishes three grades (Table  1) [34, 35]. The 
mitotic rate should be recorded. Because of tumour hetero-
geneity, a core biopsy may not provide accurate information 
about grade [36]. In addition, certain translocation-driven 
sarcomas have a relatively uniform cellular morphology and, 
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as such, can be misleadingly scored as intermediate, rather 
than high grade. This is especially true for myxoid/round 
cell liposarcomas, for which a different grading system 
based on the percentage of round cells is often used. Addi-
tional information may be provided by radiological imaging, 
and histology may be modified following assessment of the 
complete surgical resection specimen.
Pathologic diagnosis relies on morphology and 
immunohistochemistry. Increasingly it should be com-
plemented by molecular pathology to confirm those 
diagnoses characterised by a specific genetic abnormal-
ity, such as an activating mutation, chromosomal translo-
cation, or chromosomal amplification, using for example 
fluorescent in situ hybridisation (FISH), or reverse tran-
scription polymerase chain reaction (RT-PCR) [37]. It 
may have particular utility when the clinical pathologic 
presentation is unusual, or the histological diagnosis is 
doubtful. Molecular testing is now routine to confirm 
diagnoses such as Ewing sarcoma, rhabdomyosarcoma, 
synovial sarcoma, and to differentiate lipomas from atypi-
cal lipomatous tumours/well-differentiated liposarcomas.
Histology—resection
The report on the resected specimen should comply with 
the recommendations for reporting of STS produced 
by the Royal College of Pathologists [37]. The pathol-
ogy report should include an appropriate description of 
tumour depth (in relation to the superficial fascia) and 
margins (whether they are intralesional, marginal, or wide, 
and include distance from surrounding tissues, or the pres-
ence of an anatomical barrier). The pathologic assessment 
of margins should be made in collaboration with the sur-
geon, and confirmation obtained as to whether the tumour 
was excised intact. Tumour size and grade should be docu-
mented noting that the latter cannot be reliably assessed 
after pre-operative treatment with radiotherapy or sys-
temic therapy. In this setting the tumour may be assessed 
for histological response to treatment although the prog-
nostic implications are not well established, in contrast to 
their utility in osteosarcoma or Ewing sarcoma of bone.
If feasible, it is recommended that tumour samples 
should be collected and frozen, both for future research 
and because new molecular pathological assessment 
techniques may become available later that could yield 
new information of direct value to the individual patient. 
Any tissue thus obtained is governed by the Human Tis-
sue Authority; hence appropriate informed consent will 
need to be obtained from the patient.
Classification of margins
Historically, four categories of surgical margin have been 
described histologically: intralesional, marginal, wide 
and radical [38]. Whilst still included in the most recent 
ESMO guidance, they are summarised below.
Intralesional Margin runs through tumour and there-
fore tumour remains.
Marginal Surgical plane runs through pseudocapsule 
(reactive zone). The local recurrence rate is high because 
of tumour satellites in the reactive tissue. There are 
however prognostic differences between a planned and 
unplanned marginal excision.
Wide Surgical plane is in normal tissue but in the same 
compartment as the tumour. The recurrence rate is low 
and is related only to skip lesions in the affected compart-
ment.
Radical The tumour is removed including affected com-
partments and there is a minimal risk of local recurrence.
However, the recent dataset from the Royal College of 
Pathologists [37] focuses more simply on the clearance in 
millimetres of the closest surgical margin, the type of tis-
sue at the margin (e.g. fascia, fat, muscle or skin), whether 
the invasive margin is infiltrative or pushing, and presence 
or otherwise of vascular invasion. It is recognised that there 
is likely to be wide variation in the use of these descrip-
tions and a more pragmatic approach, used in other cancer 
types, may be to simply classify the margins according to 
whether there is tumour at the cut edge or not:
R0—no tumour at the cut edge.
R1—tumour extends to cut edge.
R2—macroscopic residual tumour.
Margin assessment is complex and must take into 
account both the histological subtype of the resected 
sarcoma and the nature of the R1 resection margin. A 
positive resection margin at an intentionally preserved 
critical structure (planned margin) may have quite differ-
ent prognostic significance to a multifocal R1 margin on 
the muscular surface of a resected specimen [39].
Staging
The most commonly used staging system for soft-tissue 
sarcoma, produced by the American Joint Committee 
on Cancer [40], includes information on both the grade 
Table 1 FNCLCC histological grading criteria [34, 35]
The sum of the scores of the three criteria determines the grade of malignancy. 
Grade 1 = 2 or 3; Grade 2 = 4 or 5; Grade 3 = 6
Tumour differentiation Necrosis Mitotic count (n per 10 high 
power fields)
1. Well 0: Absent 1: n < 10
2. Moderate 1: <50% 2: 10–19
3. Poor (anaplastic) 2: ≥50% 3: n ≥ 20
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(Table 1) and stage of the tumour (Table 2). The 8th edi-
tion of the staging system will be published shortly and 
include consideration of anatomical location.
The final stage groupings are not altered whether the 
tumour is superficial or deep, and are thus as follows:
Stage I
• IA = low grade, small (G1/X, T1a/b, N0, M0).
•  IB = low grade, large (G1/X, T2a/b, N0, M0).
Stage II
• IIA  =  intermediate or high grade, small (G2/3, 
T1a/b, N0, M0).
•  IIB  =  intermediate grade, large (G2, T2a/b, N0, 
M0).
Stage III
• High grade, large, (G3, T2a/b, N0, M0).
•  Regional node involvement, with any size and grade 
of primary tumour (G1-3, T1-2, N1, M0).
Stage IV
•  Metastasis identified (G1-3, T1-2, N0-1, M1).
Key recommendations
1. All patients with a suspected STS should be man-
aged by a specialist Sarcoma MDT as specified in the 
NICE guidance.
2. Ultrasound scan by a musculoskeletal radiologist should 
be considered as the first-line investigation, and may be 
supplemented by ultrasound-guided core biopsy.
3. Magnetic resonance imaging and core needle biopsy 
are recommended prior to definitive surgery.
4. Imaging of the thorax by CT scan for lung metastases 
should be done prior to radical treatment. Further 
staging may be considered depending on subtype and 
location of the sarcoma.
Management of localised disease
Soft tissue sarcomas are a diverse group of tumours and, 
as our understanding of the differing natural history and 
response to treatment improves, it is increasingly possi-
ble to tailor treatment according to the individual histol-
ogy. The major therapeutic goals are long-term survival, 
avoidance of local recurrence, maximising function, and 
minimising morbidity.
All patients should have their care managed by a for-
mally constituted sarcoma MDT. Decisions about sur-
gery, chemotherapy, radiotherapy and the timing of all 
these modalities should be made by the Sarcoma MDT. 
For site specific STS (e.g. gynaecological, head and neck) 
there should be a formal relationship between the sar-
coma MDT and the site-specific MDT. In organising ser-
vices in England reference should be made to the NICE 
quality standard for sarcoma [41] and the current NHS 
England sarcoma Service Specification [8]. The devolved 
nations may use these documents as reference but will 
have their own recommendations. Coordination with the 
sarcoma MDT helps to ensure optimal management of 
the sarcoma subtypes, recruitment to clinical trials, and 
enhances accurate data collection on sarcoma diagnoses 
and outcomes. In all cases the treatment options will be 
discussed with the patient, who should be supported by a 
specialist nurse.
For most limb and truncal tumours conservative sur-
gery, in selected cases, combined with pre- or post-oper-
ative radiotherapy is standard treatment, and achieves 
high rates of local control whilst maintaining optimal 
function. Radiotherapy may be avoided in patients with 
low-grade tumours that have been completely resected, 
or those with small, superficial high-grade tumours 
resected with wide margins.
Surgery
Surgery for localised disease
Surgery is the standard treatment for all patients with 
adult-type, localised soft tissue sarcomas, and should 
Table 2 AJCC TNM Classification for STS [40]
Physical examination, diagnostic radiology and biopsy provide the AJCC criteria 
input data needed to stage STS
Classification Description
Primary tumour (T)
 TX Primary tumour cannot be assessed
 T0 No evidence of primary tumour
 T1 Tumour ≤5 cm in greatest dimension
T1a Superficial tumour
T1b Deep tumour
 T2 Tumour >5 cm in greatest dimension
T2a Superficial tumour
T2b Deep tumour
Regional lymph nodes (N)
 NX Regional lymph nodes cannot be assessed
 N0 No regional lymph node metastasis
 N1 Regional lymph node metastasis
Distant metastasis (M)
 M0 No distant metastasis
 M1 Distant metastasis
Histologic grade (G)
 GX Grade cannot be assessed
 G1 Well-differentiated
 G2 Moderately differentiated
 G3 Poorly differentiated
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be performed by a surgeon who has appropriate train-
ing in the treatment of sarcoma. Evaluation of the 
resectability of a tumour is determined by the surgeon 
in consultation with the Sarcoma MDT, and depends 
on the tumour stage, the anatomical location, and the 
patient’s comorbidities. The primary aim of surgery is 
to completely excise the tumour with a margin of nor-
mal tissue. What constitutes an acceptable margin of 
normal tissue is not universally agreed but is commonly 
accepted as 1 cm soft tissue, or equivalent (e.g. a layer 
of fascia). However, on occasion, anatomical constraints 
mean that a true wide resection is not possible with-
out the sacrifice of critical anatomical structures (such 
as major nerves, or blood vessels) and in this situation, 
it may be acceptable to leave a planned microscopic 
positive surgical margin, having considered the risks of 
recurrence and morbidity of more radical surgery and 
having discussed these fully with the patient [42]. It is 
recognised that there is a group of low-grade tumours, 
which have a low risk of local recurrence and metasta-
sis (e.g. atypical lipomatous tumours, see “Lipomas and 
atypical lipomatous tumours” section), and it may be 
appropriate to treat these by planned marginal excision. 
In some situations, amputation may be the most appro-
priate surgical option to obtain local control and offer 
the best chance of cure.
For cases where a compartmentectomy or significant 
muscle resection to obtain clear margins will be required, 
reconstruction with free-functioning, or pedicled, muscle 
transfer may be considered at the time of primary sur-
gery. This has the advantage of a single operative episode 
for the patient, but risks performing a definitive recon-
structive procedure before clear margins have been histo-
logically confirmed.
For patients who have undergone surgery and have an 
unplanned positive margin, re-excision should be under-
taken if adequate margins can be achieved with accept-
able morbidity. Macroscopic residual disease imparts 
a poor prognosis and local control is unlikely to be 
achieved even with addition of post-operative radiother-
apy [43].
Patients with tumours that, because of size or position, 
are considered borderline resectable should be consid-
ered for neo-adjuvant treatment with chemotherapy (sys-
temic or regional), or radiotherapy [44]. This decision will 
be guided by the histology of the tumour, likely sensitivity 
to systemic treatment, and the performance status of the 
patient (see below). Pre-operative radiotherapy should 
always be considered for myxoid liposarcoma due to the 
high response rate [45]. For other subtypes however, a 
significant reduction in size of the tumour is less likely 
so the aim may instead be to devitalise the margins of an 
anticipated marginal excision.
Surgery in the presence of metastatic disease
Surgical resection of the primary tumour remains an 
option as a palliative procedure in patients with meta-
static disease. However, radiotherapy or chemotherapy 
may be more appropriate and the decision must take 
into account factors such as the patient’s likely progno-
sis, symptoms (e.g. pain or ulceration), co-morbidity, the 
expected morbidity of surgery, histological sub-type and 
the extent of metastases.
Isolated limb perfusion
Where available, isolated limb perfusion (ILP) may be 
a useful pre-operative technique for reducing the size 
of difficult, but potentially resectable, tumours in an 
extremity where limb preservation may not otherwise 
be possible. ILP employs local high-dose chemotherapy 
(melphalan) plus tumour necrosis alpha (TNFα), and 
hyperthermia, restricted to the affected limb using arte-
rial and venous cannulation and a tourniquet. ILP has 
been shown to shrink peripheral tumours, thus render-
ing them operable, and should be considered in selected 
cases [46, 47]. It is also of particular importance as an 
adjunct to surgical resection for local recurrence in the 
post-radiotherapy setting where further radiotherapy 
cannot be delivered and close margins are likely. In addi-
tion, ILP may be considered for palliation of unresectable 
sarcomas that would otherwise require an amputation, 
although if the tumour subsequently remains inoper-
able the durability of response is limited. Currently there 
is only limited availability of this service for STS, at the 
Royal Marsden Hospital in London, and the Beatson 
Cancer Centre in Glasgow.
Radiotherapy
Adjuvant radiotherapy
Both pre- and post-operative radiotherapy are considered 
to be standard approaches for most intermediate or high-
grade soft tissue sarcomas. The addition of radiotherapy 
to surgery allows preservation of function with similar 
local control rates, and survival, to radical resection (i.e. 
compartmental excision/amputation) [48]. The major-
ity of patients with low-grade tumours will not require 
radiotherapy. However, it should be considered for those 
with large, deep tumours with close or incomplete mar-
gins of excision, in whom re-excision is not possible, 
especially if adjacent to vital structures that could limit 
further surgery in the future. Patients who have under-
gone a compartmental resection or amputation do not 
require adjuvant radiotherapy assuming that the margins 
are clear.
The recommended post-operative radiation dose is 
60–66 in 1.8–2 Gy fractions [49]. A two-phase technique 
using a shrinking field is commonly employed for limb 
Page 8 of 26Dangoor et al. Clin Sarcoma Res  (2016) 6:20 
sarcomas; 50 Gy to the initial larger volume followed by 
10–16 Gy to a smaller volume [49]. This dose may need 
to be reduced if the field includes critical structures 
(for example the brachial plexus). Intensity-modulated 
radiation therapy (IMRT) should be considered to opti-
mise the treatment volume, improve dose conform-
ity, and reduce toxicity [50]. A phase II study of IMRT 
for sarcoma is underway in the UK, and ideally patients 
should be treated within the trial setting (IMRiS. Health 
Research Authority) [51].
The VORTEX clinical trial of post-operative radio-
therapy for extremity soft-tissue sarcomas has completed 
recruiting in the UK [52]. This randomised clinical trial 
is comparing the standard post-operative two-phase, 
shrinking field, radiotherapy technique, with a single 
phase applied to a smaller treatment volume. The aim 
is to potentially spare normal tissue, and hence improve 
subsequent limb function, without compromising local 
control. The preliminary results of the study should be 
available in 2016 and may influence standard practice.
Pre-operative radiotherapy in limb sarcoma utilises a 
lower dose of 50  Gy as well as a smaller treatment vol-
ume covering the pre-operative tumour volume rather 
than the post-operative tumour bed. It has been shown 
to be associated with increased acute, post-operative 
complications compared to the standard post-operative 
treatment, but less late toxicity, with equivalent tumour 
control [53, 54]. In the UK, pre-operative radiotherapy 
has become routine in some centres. It may be preferred 
particularly where the size of the radiation field required 
for post-operative treatment is likely to be associated 
with significant late morbidity, or when the tumour is 
of borderline operability and pre-operative radiotherapy 
might render the tumour operable [44], or devitalise the 
margins of an anticipated marginal excision. If pre-oper-
ative radiotherapy is used there is a slightly higher inci-
dence of post-operative morbidity including acute wound 
healing problems. Approaches which include the use of 
local or free flaps might be advantageous to avoid wound 
complications. Free flaps may reduce the risk of post-
operative wound breakdown, minimise the dead space, 
and reconstruct the defect. A two team surgical approach 
(resection and reconstruction) reduces the operative 
time. Pre-operative radiotherapy may be less appropri-
ate in cases where wound healing is more likely to be 
problematic, such as proximal thigh/groin or axillary 
locations. In addition, if a patient has a rapidly growing, 
painful tumour early surgery may be preferred. For cer-
tain radiosensitive histological subtypes, such as myxoid 
liposarcoma, pre-operative radiotherapy may be particu-
larly advantageous, given the degree of tumour shrink-
age that can be achieved [44, 45]. The standard regimen 
for pre-operative radiotherapy is 50  Gy, over 5  weeks, 
followed by surgery approximately 4–6 weeks after com-
pletion of radiotherapy. A further 10–16 Gy may be given 
post-operatively if tumour margins are positive, after 
careful consideration, although recent evidence suggests 
this is unlikely to be beneficial and may result in excess 
late toxicity [55].
Definitive radiotherapy
The use of radiotherapy alone is unusual in the treatment 
of sarcoma. However, in a small number of cases the sar-
coma may be considered unresectable due to location, 
local invasion, or because resection would lead to unac-
ceptable morbidity or a poor functional outcome. In these 
cases, radiotherapy can occasionally provide a durable 
remission although local recurrence rates are high. Out-
comes appear related to tumour size, grade, and radiation 
dose [56–59]; doses of over 60 Gy may be employed. In 
patients with significant life-limiting comorbidities lower 
dose, palliative radiotherapy is an option.
Proton therapy
Proton therapy is a highly specialised method of deliv-
ering high-dose radiotherapy to a target volume, whilst 
minimising dose to surrounding normal tissue. It is con-
sidered for a number of defined indications which may 
include spinal or paraspinal soft-tissue sarcomas in both 
adults and children [60]. It is commissioned by NHS Eng-
land where applications for treatment are considered by 
a “Proton Panel”. Currently patients are sent overseas for 
treatment, but two new facilities are under construction 
at The Christie NHS Foundation Trust in Manchester 
and University College Hospital (UCLH) NHS Founda-
tion Trust. The services in these centres are due to com-
mence in 2018 and 2019 [61].
Chemotherapy
Adjuvant chemotherapy
The role of adjuvant chemotherapy for most STS remains 
unproven. Although currently not regarded as standard 
treatment in the UK, there is conflicting evidence, and 
it may be considered for individual patients with higher 
risk tumours and potentially chemo-sensitive subtypes 
on the basis that benefit cannot be excluded. Table 3 pro-
vides a general guide as to likely relative chemosensitiv-
ity. Due to a lack of published comparative data the table 
is based on the referenced paper [62], modified in light 
of the clinical experience of the authors and reviewers 
of these guidelines. In most cases treatment of relapsed 
disease is palliative and the best chance of obtaining 
cure is therefore with primary treatment. In those sub-
types with particularly poor prognosis, such as cardiac 
sarcoma, where salvage treatment for relapse would be 
difficult, the threshold for using adjuvant chemotherapy 
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may be lower. It may also be considered in other situa-
tions where local relapse would be untreatable or where 
adequate radiotherapy could not be administered owing 
to the sensitivity of adjacent structures, for example spi-
nal cord. A meta-analysis published in 1997 reported an 
improvement in local control and progression free sur-
vival; however, although there was a trend towards an 
overall survival benefit this was not statistically signifi-
cant [63]. These data have been supported by two more 
recent overviews [64, 65]. The latter did not use original 
trial data and included a large Italian trial which, when 
published in 2001, reported a significant survival ben-
efit for adjuvant chemotherapy; although this has not 
been maintained with long-term follow-up [66]. The final 
data from EORTC 62,931 [67], the largest trial of adju-
vant chemotherapy for STS, have failed to demonstrate 
any clear benefit from chemotherapy in local control, 
relapse-free survival or overall survival in patients treated 
with adjuvant chemotherapy. Interestingly however, it 
did demonstrate improved survival in both study arms 
compared with previous trials, perhaps due to improved 
surgical techniques and increased use of adjuvant 
radiotherapy.
One of the issues with trials of adjuvant treatment up 
until now is the blanket approach of a standard chemo-
therapy combination for all sarcomas. It is hoped that as 
more effective treatments are developed for specific sar-
coma subtypes, these could be tested in the adjuvant set-
ting with a greater chance of benefit.
Neo‑adjuvant chemotherapy
The data to support neo-adjuvant chemotherapy for STS 
is mainly limited to retrospective series, and phase 2 tri-
als [68]. However pre-operative chemotherapy, or chem-
oradiotherapy, may be considered for those patients with 
large high-grade tumours that are considered borderline 
resectable by the sarcoma MDT [69]. The age, and any 
comorbidity of the patient, together with the histology of 
the tumour need to be taken into account. There is a wide 
variation in chemosensitivity between different histologi-
cal subtypes (Table  3). If the tumour is chemosensitive 
and adjacent to critical organs, then chemotherapy may 
potentially render the tumour suitable for conservative 
surgery whereas otherwise more radical surgery would 
be necessary. For example, for synovial sarcoma response 
rates of 28% [70] in a recent review of European trials, 
to over 50% in a single-centre series, have been reported 
[71, 72]. Similarly, myxoid liposarcomas are considered to 
be significantly more responsive than the majority of STS 
[72, 73], although radiotherapy alone may be sufficient 
[44]. With variable response of individual tumours to 
chemotherapy, the tumour should be monitored closely 
due to the risk of progression on treatment, in which case 
surgery can be expedited.
Key recommendations
 1. Surgery is the standard treatment for most patients 
with localised STS.
 2. For those patients with resectable disease, a wide 
excision through normal uninvolved tissues is the 
surgical procedure of choice.
 3. Defining a “wide” margin is controversial, but with 
the addition of effective adjuvant therapy (e.g. radio-
therapy) a tumour free margin (R0) may be adequate.
 4. Where a wide excision is not possible due to ana-
tomical constraints, a planned marginal or micro-
scopically positive margin against a critical structure, 
plus radiotherapy, for intermediate and high grade 
tumours, may be an appropriate means of achieving 
tumour control while maintaining physical function.
 5. Occasionally, amputation should be undertaken as 
the only surgical option to achieve adequate mar-
gins.
 6. For patients with borderline resectable tumours, pre-
operative treatment with chemotherapy and/or radio-
therapy should be considered depending on histology.
 7. Pre- or post-operative radiotherapy is recommended 
along with surgical resection of the primary tumour 
for the majority of patients with high-grade tumours, 
Table 3 Soft tissue sarcomas grouped by chemosensitivity
Modified from R. Salgado and E. van Marck [62] by a consensus view of the 
authors and other guideline contributors
Relative chemosensitivity Examples of soft tissue sarcomas
Chemotherapy integral to manage-
ment
Ewing’s sarcoma family tumours
Embryonal and alveolar rhabdo-
myosarcoma
















Chemoinsensitive Alveolar soft part sarcoma
Extraskeletal myxoid chondrosar-
coma
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and for selected patients with large or marginally 
excised, low-grade tumours.
 8. The recommended dose for post-operative radio-
therapy is 60–66 Gy.
 9. Pre-operative radiotherapy is advantageous in terms of 
better long-term functional outcome, with equivalent 
rates of disease control, when compared with post-
operative radiotherapy. There is however an increased 
risk of acute post-operative wound complications.
 10. The recommended dose for pre-operative radiother-
apy is 50 Gy.
 11. Adjuvant chemotherapy is not routinely recom-
mended but could be considered in situations where 
achieving local control is likely to be compromised, 
or the risk of metastatic disease is particularly high, 
with a lower threshold for its use in the more che-
mosensitive sarcoma subtypes.
Prognosis and follow‑up for primary disease
Prognosis following primary treatment can be estimated 
by well-established nomograms based on grade, depth, 
size, and diagnosis as well as patient age [74]; some spe-
cialist centres have made online calculators available [75]. 
It appears that outcomes may have improved over the 
past 20 years [76], although NCIN data are less convinc-
ing [12]. Local recurrence is related to grade, margins of 
excision, and use of radiotherapy. Whilst most events will 
arise in the first 5 years following diagnosis late relapses 
may occur, according to this French Sarcoma Group study, 
particularly in retroperitoneal or very large STS [77].
In common with other tumour sites, there are few pub-
lished data supporting specific follow-up protocols for 
STS patients, and there is an urgent need for research. 
Patients may be reassured by follow-up, and early detec-
tion of local relapse or pulmonary metastases may 
improve prognosis in some patients. Follow-up should be 
discussed with the patient and the rationale and limita-
tions explained.
A survey on follow-up illustrated how varied the 
approach is at different centres, with no agreement on 
imaging, follow-up intervals, or total duration of follow-
up [78]. Practices such as discharging patients treated 
for low-grade tumours at 5  years, when evidence sug-
gests they recur late, require review. A recently reported 
trial comparing standard follow-up, with greater inten-
sity follow-up and more imaging, failed to show any 
difference in outcome [79]. Furthermore, a recent retro-
spective study of follow-up for detection of local recur-
rence, demonstrated that most are detected clinically, 
casting doubt on the utility of routine surveillance MRI 
scanning [80].
It is recommended that standard follow-up consists of:
1. Clinical history,
2. Clinical examination to focus on local recurrence, 
with imaging using ultrasound or MRI where indi-
cated by clinical suspicion, or if the primary site is 
difficult to examine clinically (e.g. pelvic tumours),
3. Chest X-ray, with subsequent CT used for investigat-
ing abnormalities.
4. Monitoring for late-effects of treatment.
In certain cases, this standard follow-up can be 
extended or adapted according to individual risk or local 
practice. If a patient were deemed unfit either for pul-
monary metastasectomy or systemic treatment, then 
diagnosing metastases when the patient is asymptomatic 
has little purpose, so for example, the chest X-ray could 
be dispensed with; indeed, referral back to primary care 
might be most appropriate.
As per the ESMO guidelines [28], it is recommended 
that patients with intermediate/high grade tumours, 
which most commonly relapse within 2–3 years, should 
be followed every 3–4 months in the first 2–3 years, then 
twice a year up to the fifth year, and once a year thereaf-
ter for a minimum of 8–10 years. It is recommended that 
patients with low-grade tumours should be followed up 
every 4–6  months for 3–5  years, then annually thereaf-
ter, for at least 10 years. In low-grade sarcoma where the 
risk of local recurrence is the main reason for follow-up, 
suitably educated patients, with tumours resected from 
easily examined regions can be considered for discharge 
from formal follow-up, with an option to self-refer back 
to the service if any abnormality is identified.
A further value of follow-up is to monitor for adverse, 
late effects of treatment. Patients who have received radi-
otherapy may, for example be at risk of second malignan-
cies or accelerated atherosclerosis in the radiotherapy field. 
Following chemotherapy there may be deterioration of 
renal function, and reduced fertility. In women, early men-
opause may require interventions for issues such as bone 
health. Investigations for late-effects of treatment should 
be considered such as full blood count, renal profile, hor-
mone profile, and echocardiography. Patients treated in 
childhood for paediatric sarcomas may be handed on to 
adult services, and it is important that suitable follow-up 
continues. Survivorship is an area of cancer management 
on which there has been more focus in recent times. Physi-
cal disability is a major feature of the survivorship experi-
ence of patients treated for soft tissue sarcoma [81], and 
follow-up should support the patient in trying to mini-
mise the impact of their treatment. Low activity levels put 
sarcoma survivors at further cardiovascular risk, which 
should be considered when constructing a follow-up 
regimen.
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Key recommendations
1. It is recommended that patients with intermedi-
ate or high-grade sarcoma are followed up every 
3–4 months for the first 2–3 years, then twice a year 
for up to 5 years, and annually thereafter for a total of 
8–10 years.
2. Patients with low-grade sarcoma should be followed 
up every 4–6 months for 3–5 years, then annually.
3. Standard follow-up practice should consist of:
a. Review of any new symptoms reported by the 
patient,
b. Clinical examination to focus on local recur-
rence, with imaging follow-up where indicated 
by clinical suspicion,
c. Routine chest X-ray to exclude pulmonary 
metastases,
d. Monitoring for late-effects of treatment.
4. New models of follow-up warrant further investiga-
tion.
Prognosis and treatment of advanced disease
In almost all cases, the treatment intention for metastatic 
disease is palliation. Approximately 50% of patients with 
high-grade sarcoma develop distant metastases and even-
tually die of disseminated disease, with a median survival 
of approximately 12  months from diagnosis of metasta-
ses [82–84]. There are more recent data suggesting that 
this survival figure may be rather conservative with some 
improvement in outcomes over time to a median of 
around 18 months [85, 86].
The management of advanced disease is complex; the 
approach to palliative treatment depends to some extent 
on whether or not symptoms are present, and the poten-
tial toxicities of treatment. In order to achieve control of 
symptoms such as pain, or dyspnoea, it is often neces-
sary to achieve some degree of tumour shrinkage. Clearly 
however in the absence of significant symptoms, disease 
stabilisation is an equally valid aim, to prolong good qual-
ity of life. A consistent finding in studies of soft tissue 
sarcoma is that overall survival, as in GIST [87, 88], is 
defined by absence of disease progression, not degree of 
response.
The treatment of advanced disease may involve a com-
bination of various strategies, often used in a stepwise 
fashion, particularly for those patients with a prolonged 
disease course. The options will take into account the dis-
ease histology, distribution, volume, plus likely sensitiv-
ity to systemic treatment. Along with systemic treatment, 
surgery and radiotherapy may be considered to target 
symptomatic metastases or in an attempt to prolong the 
remission period. Other techniques, such as microwave 
or radiofrequency ablation, may have a role. Medications 
for pain or other complications such as bone metastases 
may be considered. Bisphosphonates or denosumab may 
be useful in reducing fracture risk or bone pain, based on 
data from other cancers, although radiotherapy or sur-
gery may also be indicated. In some patients, metastases 
may behave fairly indolently and periods without active 
treatment are often appropriate. Other areas to focus on 
are good supportive care, potentially involving special-
ist palliative care services, in coordination with primary 
care.
For a number of patients, particularly those with poor 
performance status or significant comorbidities, stand-
ard supportive care with symptom control alone, is often 
the most appropriate option. Early involvement of com-
munity palliative care teams should be considered in all 
patients with advanced disease.
Systemic anti‑cancer therapy (SACT) for sarcoma
The development of optimal treatment protocols is ham-
pered by the rarity and heterogeneity of sarcoma. The 
incidence of many of the individual sub-types of soft tis-
sue sarcoma is too small to permit large-scale prospective 
randomised controlled trials. Accordingly, data are gath-
ered from a range of studies which include single-site and 
multisite phase 2 trials, retrospective case series, sub-
analyses of trials for which a range of histological sub-
types are included and, for the rarer sub-types, individual 
case reports.
A national algorithm produced by the NHS England 
Sarcoma Clinical Reference Group (CRG) has been pro-
posed to guide the systemic treatment of sarcoma in Eng-
land; a draft is under review. This is likely to be endorsed 
by the British Sarcoma Group and should therefore be 
used alongside this guideline.
The published response rates for chemotherapy in STS 
vary enormously, from 10 to 50% depending on the drugs 
used, patient selection, and histological subtype (Table 3). 
It has been established that good performance status, 
young age, and absence of liver metastases predict a good 
response to chemotherapy and improved survival time 
[83]. It is increasingly understood that response rate is 
only one measure of treatment efficacy with many of the 
newer therapies leading to a clinical benefit through dis-
ease stabilisation. A differential response to chemotherapy 
according to histological subtype has been noted, and as 
knowledge increases it is expected that it will become 
increasingly possible to individualise treatment. For 
example; synovial sarcoma, leiomyosarcoma and myxoid 
liposarcoma are recognised as having higher response 
rates to chemotherapy. Conversely, alveolar soft part sar-
coma, extraskeletal myxoid chondrosarcoma and solitary 
fibrous tumour are generally regarded as insensitive to 
chemotherapy, and there are only occasional reports of 
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responses in clear cell sarcoma. However, in the era of tar-
geted therapies merely looking at response rates to stand-
ard chemotherapy is starting to be superseded by more 
specific relationships between histology and therapeutics.
Current and future trials are focusing on targeting new 
therapies more specifically, utilising genomic profiling, a 
better understanding of tumourogenesis, and the mecha-
nisms of drug activity. In addition, a better understanding 
of the immune system has led to the development of new 
agents such as the immune-checkpoint inhibitors which 
are showing great promise in other tumour types. A sig-
nificant challenge in sarcoma management is that given 
the rarity of the disease, and the numerous subtypes, it is 
difficult to perform large enough trials to gain the gold-
standard, randomised evidence, that is preferred when 
developing treatment recommendations. It therefore 
means that, in contrast to other cancers, treatment may 
be given on the basis of phase II trials, small randomised 
phase III trials, and even for the very rare subtypes, 
case series. It is important therefore, where possible to 
develop multicentre clinical trials and recruit patients 
into them. Increasingly it is clear that rather than treat-
ing sarcoma as one condition, systemic treatment should 
be tailored to the histology or genetics of the individual 
subtype [89–91].
Selection of SACT
As noted above, in the UK the proposed national SACT 
Algorithm should guide systemic treatment of sarcoma. 
In addition, treatment of advanced disease may involve 
other modalities such as radiotherapy or surgery, and 
so multidisciplinary team review is important. Systemic 
treatment should ideally be guided by established proto-
cols, preferably shared nationally. There is potential vari-
ability in dosing and administration, particularly in the 
use of agents such as ifosfamide, and care should be taken 
to use treatment protocols that maximise benefit whilst 
ensuring optimal management, and minimisation, of 
potential toxicities. Techniques such as the use of ambu-
latory infusions can be used to enhance patient conveni-
ence, and free-up valuable inpatient resources [92].
In a cost-constrained health system there is a challenge 
to fund all active agents, particularly in rare diseases. 
Some of the treatments considered may fall outside cur-
rent standard NHS funding, and this will have to be taken 
into account when discussing the options with patients.
In most cases of metastatic soft-tissue sarcoma the 
choice of first-line chemotherapy will be between single-
agent doxorubicin, or combined doxorubicin and ifos-
famide. The latter combination has not been shown to 
improve survival, although delivers a higher response 
rate at a cost of increased toxicity [84, 93]. This may be an 
important consideration if the patient is symptomatic due 
to tumour size, or a reduction in tumour volume might 
facilitate other treatment options. The performance sta-
tus of the patient and comorbidities will play an important 
role in treatment selection particularly in view of potential 
cardiac toxicity of doxorubicin and renal toxicity seen with 
ifosfamide. Treatment dose is also a consideration with 
higher doses shown to potentially improve efficacy [94].
Standard second-line treatment is ifosfamide, which is 
also used first-line where anthracyclines are contraindi-
cated, for example in patients at high risk of cardiac com-
plications, or patients pre-treated with anthracyclines. 
Clinical trials have indicated a dose–response relation-
ship, and a dose of 9–10 g/m2 is recommended [95]. In 
unselected sarcomas the response rate is in the region of 
8%, although higher response rates have been observed 
with high-dose (>12 g/m2) and continuous infusion ifos-
famide regimens [28, 96, 97]. Responses may be higher 
in certain subtypes such as synovial sarcoma, whilst leio-
myosarcoma is arguably less responsive and alternative 
agents may be more appropriate [98]. Ifosfamide is usu-
ally given over two to three days as an inpatient, but more 
recently infusional regimens administering treatment via 
a pump over two weeks have been utilised [99]. Treat-
ment given in this way is usually better tolerated, but so 
far is most established in retroperitoneal liposarcoma, 
and is not yet a standard of care. Renal toxicity of ifosfa-
mide can be significant and close monitoring is required. 
More rarely neurotoxicity is seen; more often in debili-
tated patients with low albumin levels.
An alternative second-line option is the combination 
of gemcitabine and docetaxel. The evidence for gemcit-
abine and docetaxel is greatest for uterine leiomyosar-
coma. However, subsequent studies have demonstrated 
activity in soft tissue leiomyosarcoma and other tumour 
types including undifferentiated pleomorphic sarcoma 
[100, 101]. The GeDDiS trial in which this regimen was 
compared with doxorubicin in the first-line setting for all 
sarcoma subtypes, showed it to be non-inferior, but more 
toxic [102].
Trabectedin, licensed as second-line treatment for 
all soft tissue sarcomas, was approved by the European 
Medicines Agency (EMA) on the basis of a randomised 
trial comparing two different treatment regimens in 
patients with predominantly leiomyosarcoma and lipo-
sarcoma [103]. A recently completed trial in patients 
with leiomyosarcoma and liposarcoma comparing tra-
bectedin with dacarbazine demonstrated significant 
superiority for trabectedin resulting in the drug being 
licensed in the USA [104]. Other tumours, such as syn-
ovial sarcoma, and particularly myxoid liposarcoma, 
may also be sensitive. It appears to be active in sarco-
mas related to chromosomal translocations [105, 106]. 
When assessing clinical benefit, it should be noted that a 
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period of disease stabilisation may often occur for some 
time before response is seen. Trabectedin is currently 
approved by NICE and treatment can continue until dis-
ease progression. It exhibits less haematological toxicity 
than doxorubicin or ifosfamide but prescribers need to 
be aware of rare, but potentially serious rhabdomyolysis, 
and hepatic toxicity.
Beyond doxorubicin, ifosfamide, gemcitabine/doc-
etaxel, and trabectedin, there are no standard chemother-
apy options and decisions will be made based on patient 
fitness, and a balance of likely benefit and toxicities. 
Consideration of previous clinical benefit from chemo-
therapy, and more chemo-sensitive subtypes of sarcoma 
may support further treatment. Below are a number of 
options included in the proposed Sarcoma Chemother-
apy Algorithm:
  • Liposomal doxorubicin (Caelyx): could be considered 
at any line for vascular intimal sarcomas, angiosarco-
mas [107], cardiac sarcomas, and patients who have 
received previous anthracyclines, or have impaired 
cardiac function [108]. It can be combined with 
ifosfamide. It also has activity in fibromatosis (see 
“Desmoid-type fibromatosis” section).
  • Paclitaxel: may be used as first or second line treat-
ment of angiosarcomas [109].
  • Oral cyclophosphamide and prednisolone: a low tox-
icity combination suitable for elderly patients unlikely 
to tolerate more toxic chemotherapy [110].
  • Pazopanib: has data supporting its use in meta-
static STS (not liposarcoma). A placebo controlled 
study demonstrated a 3-month improvement in 
progression-free survival in STS, with no particu-
lar superiority in any individual subtype. [111, 112]. 
Of note, activity was also seen in refractory desmo-
plastic small round cell tumour. This class of VEGFR 
inhibitor (including sunitinib) has also demonstrated 
activity in haemangiopericytoma/malignant solitary 
fibrous tumour [113], which is relatively resistant to 
chemotherapy (although see dacarbazine below), and 
in refractory desmoid tumours/fibromatosis [114].
  • Dacarbazine: in the past used more commonly in 
STS, it has come to be used primarily for leiomyosar-
coma, either as a single agent or in combination with 
gemcitabine [115]. Activity has also been reported 
against solitary fibrous tumour/haemangiopericy-
toma [116].
It should be noted that not all active agents mentioned 
above are currently funded by the NHS in the UK for the 
indications described. Funding varies across the devolved 
nations and is regularly under review.
Although not yet appraised by NICE, or commonly 
used in the UK, in April 2016 eribulin received market-
ing authorisation from the European Medicines Agency 
(EMA) for the treatment of unresectable liposarcoma 
following prior anthracycline-containing therapy. This 
followed subgroup analysis of a study comparing eribu-
lin with dacarbazine for previously treated patients with 
liposarcoma or leiomyosarcoma [117].
Management of local recurrence
Local recurrences are often accompanied by metastatic 
disease and patients should be carefully staged for this. 
In the absence of overt metastatic disease every attempt 
should be made to regain local control by further surgery 
with adequate margins (wide or radical), and radiother-
apy (if not used previously). Amputation may be needed 
in selected cases.
Management of lung metastases
Following a diagnosis of lung metastases, the deci-
sion regarding metastasectomy should be based on dis-
ease-free period following primary surgery, absence of 
other metastases, number of lesions per lung, tumour 
growth, and evolution of disease (ESMO 2014) [28]. In 
the absence of a significant disease-free interval, the 
CT scan (or PET-CT scan to complete staging) should 
be repeated at a three-month interval, and if no new 
lesions have appeared and the disease is operable, sur-
gery is usually recommended. The practice of performing 
an interval scan and delaying surgery can be difficult to 
explain to patients, but the risk of immediate surgery is 
that further multiple metastases appear rapidly, render-
ing the morbidity of surgery pointless, and potentially 
delaying systemic treatment. Other approaches can also 
be considered such as radiofrequency or microwave abla-
tion. More recently stereotactic ablative radiotherapy 
(SABR), a very targeted form of high-dose hypo-frac-
tionated radiotherapy, has become another potential 
option. While there are few data from prospective studies 
reporting survival of STS patients surgically treated for 
thoracic metastases, there are many long-term survivors 
(reported variously at 20–40% of all patients undergoing 
lung surgery) who have had the procedure [118]. It how-
ever remains unproven that metasectomy improves long 
term survival.
Management of extrapulmonary oligometastases
In most cases extrapulmonary metastases will be 
treated with systemic treatment. In selected cases sur-
gery, radiofrequency ablation (RFA), cryotherapy, or 
radiotherapy may be considered for limited metastatic 
disease to prolong remission or reduce symptoms. 
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Electrochemotherapy (ECT) is an emerging technique 
that may be useful in the management of refractory der-
mal and subcutaneous metastases in certain tumour sub-
types, for example angiosarcoma [119, 120].
Best Supportive Care
Supportive and palliative care should always be consid-
ered in cases of advanced disease. For many patients, 
systemic therapy, radiotherapy, or surgery may not 
be appropriate, and an early and honest conversa-
tion about treatment options, potential toxicities 
and quality of life is important. Involvement of a sar-
coma specialist nurse to support the patient through 
the diagnostic process and discussion of options can 
be invaluable. Early referral to specialist palliative 
care services in the community should be considered. 
Although prognostication can be difficult and inexact, 
most patients and their families will want some idea of 
likely outcomes and this should be explored with them. 
Discussions concerning end-of-life care preferences 
may also be appropriate.
Key recommendations
1. Systemic treatments for the majority of advanced 
STS are not curative; median survival time is 
12–18  months. Published chemotherapy response 
rates vary enormously; from 10–50% depending on 
the drugs used, patient selection, and tumour grade 
and histological subtype.
2. Treatment recommendations should be guided by 
patient performance status, disease extent, rate of 
progression, and potential sensitivity to treatment.
3. Standard first-line treatment is single-agent doxoru-
bicin.
4. Ifosfamide may be used first-line if anthracyclines are 
contraindicated, and is a standard option for second-
line therapy.
5. Although the combination of doxorubicin and ifosfa-
mide has not been demonstrated to improve survival 
in comparison to single agent doxorubicin first-line, 
response rates are higher and it may be considered in 
individual patients where a response would improve 
symptoms or facilitate other treatment modalities.
6. Additional second-line agents include trabectedin, 
and the combination of gemcitabine and docetaxel. 
The choice of agent depends on histology, toxicity 
profile and patient preference.
7. A number of other agents such as dacarbazine and 
pazopanib can be considered beyond second-line 
depending on patient fitness and funding constraints.
8. Surgical resection of locally recurrent disease should 
be considered where feasible. For patients with oli-
gometastatic disease surgery, radiotherapy, or abla-
tive therapies (RFA, SABR, cryotherapy, microwave, 
ECT) should be considered in individual cases, 
although there are limited data on survival benefit.
Uterine and retroperitoneal sarcomas
Given the heterogeneity of sarcoma presentations many 
patients are managed in collaboration with other mul-
tidisciplinary teams. For England, reference should 
be made to the NICE Quality Standard, QS78 [41] and 
National Sarcoma Service Specification [8]. The MDTs 
should combine expertise to ensure optimal manage-
ment taking into consideration tumour location, and sub-
type. Uterine sarcomas in the UK are usually managed 
primarily by regional gynaecological cancer MDTs, but 
strong links to the sarcoma MDT should be maintained 
to ensure that patients are appropriately registered, 
managed, considered for clinical trials, and referred for 
systemic treatment if required for metastatic disease. 
Retroperitoneal sarcomas should be managed by sur-
geons who are members of the sarcoma MDT although 
not every UK STS centre will have this service available 
and cross-referral may be required. Gastrointestinal stro-
mal tumours (GIST) are usually managed in collabo-
ration with GI surgical services, and are discussed in 
separate BSG guidance.
Uterine sarcomas
This group includes uterine leiomyosarcomas (LMS), 
endometrial stromal sarcomas (ESS), and undifferenti-
ated endometrial sarcoma (UES). Standard treatment 
for all localised tumours is total abdominal hysterectomy 
(TAH), with some differences between the tumour types 
as described below [28]. Carcinosarcomas (malignant 
mixed Mullerian tumours, MMMT) are considered as 
epithelial tumours and, although new biological insights 
are emerging [25], should be treated accordingly, unless 
the sarcomatous element predominates.
Uterine leiomyosarcoma
Uterine LMS, a cancer of the smooth muscle, accounts 
for 35–40% of all uterine sarcomas; LMS can affect 
young women in their mid-20 s, although most patients 
will be aged 50–60 years. Pre-operatively it is difficult to 
differentiate benign leiomyomas from malignant LMS 
and so the surgical approach should be planned accord-
ingly; laparoscopic morcellation is contraindicated for 
uterine sarcoma due to higher risk of recurrence and 
metastasis [121–123]. The risk of inadvertent morcella-
tion of a uterine sarcoma increases significantly with age 
[124], and the US Food and Drug Administration (FDA) 
released a safety communication concerning the proce-
dure in 2014 [125]. Standard surgical management for 
non-metastatic disease is total abdominal hysterectomy 
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(TAH) with, or without bilateral salpingo-oophorectomy 
(BSO). Retention of the ovaries can be considered in pre-
menopausal women. Lymphadenectomy is not routinely 
required as incidence of lymph node involvement is less 
than 5%. Adjuvant pelvic radiotherapy for FIGO stage I 
and II disease is not recommended routinely [126]. Adju-
vant pelvic radiotherapy may be considered for selected 
high-risk cases, for example after tumour rupture, where 
local relapse may be reduced, although a survival ben-
efit has not been demonstrated [127]. Adjuvant chemo-
therapy is not routinely recommended but, as for other 
STS, can be considered in high-risk disease where there 
is some limited evidence [128, 129]. Chemotherapy for 
advanced/metastatic disease is as for STS at other sites, 
with doxorubicin as first line, although ifosfamide may be 
relatively less effective in LMS [98]. The combination of 
gemcitabine and docetaxel has demonstrated activity in 
the second-line setting in leiomyosarcoma. Trabectedin 
also seems to have useful activity [130].
Oestrogen receptor (ER) and progesterone receptor 
(PgR) expression is seen in approximately 50% of patients 
with uterine LMS. Some low and intermediate grade 
tumours may be sensitive to oestrogen deprivation, e.g. 
using aromatase inhibitors, although there are very few 
published data on this situation [131]. It is however rea-
sonable to look for receptor expression in those with 
relatively indolent tumours for which treatment with an 
aromatase inhibitor or a progestogen might be appropri-
ate. However, receptor expression does not guarantee 
response to oestrogen-lowering therapy, and use of oes-
trogen-lowering therapies should be used with particular 
caution in patients with high-grade rapidly progressing 
tumours.
Endometrial stromal sarcoma
Although a rare uterine malignancy, this is the second 
most prevalent uterine sarcoma, and a generally indo-
lent disease with a long natural history. It was formally 
known as “low grade ESS”, on the basis of a mitotic count 
of less than 10 mitoses per 10 high powered fields, but 
is now termed simply ESS, with no distinction between 
“grade” (mitotic count is now recognised not to be prog-
nostic). There is a high incidence of oestrogen (ER) and 
progesterone receptor (PR) expression, and evidence 
that these tumours are hormonally responsive. Standard 
surgical treatment is therefore total abdominal hysterec-
tomy, with bilateral salpingo-oophorectomy in pre-men-
opausal women; hormone replacement therapy (HRT) 
is contraindicated postoperatively [132]. A single small 
study has suggested that adjuvant progestogens after sur-
gery may improve outcome; routine use is not indicated 
but could be considered in high risk patients [133]. The 
role of adjuvant pelvic radiotherapy is uncertain given 
the paucity of published data. Recurrent or metastatic 
disease may respond to anti-oestrogen therapy, with an 
aromatase inhibitor, or a progestogen. Tamoxifen is not 
recommended since its action may be pro-oestrogenic 
in this setting. Chemotherapy is an option if hormonal 
therapy fails. Given the indolent nature of the condition, 
surgery for metastatic disease should be considered.
Undifferentiated endometrial sarcoma
This disease entity was formally known as “high grade 
ESS”, but is now termed undifferentiated endometrial 
sarcoma (UES). It is a highly aggressive anaplastic malig-
nancy that does not express ER and PR, with a poor prog-
nosis even for early stage disease, and uncertain response 
to systemic treatment. Surgical management is TAH with 
or without BSO, and the option of adjuvant pelvic radio-
therapy [126]. Follow-up protocols and systemic treat-
ment for advanced disease parallel those for adult-type 
soft tissue sarcomas [28]. Oestrogen-lowering therapies 
are generally not used.
There has been some reported success with cisplatin 
in treating uterine sarcomas but figures are distorted 
because of high numbers of carcinosarcoma/malignant 
mixed Mullerian tumour (MMMT) patients in the only 
large trial. No subset analysis has been offered, therefore 
this drug is not recommended.
Key recommendations
1. Standard treatment for all localised uterine sarcomas 
is TAH. Lymphadenectomy is not routinely indi-
cated.
2. Total abdominal hysterectomy, with bilateral oopho-
rectomy is indicated for endometrial stromal sar-
coma. These patients should not have post-operative 
hormone replacement therapy, and tamoxifen is con-
traindicated. Use of adjuvant oestrogen deprivation 
therapy is not routinely indicated.
3. Adjuvant pelvic radiotherapy has not been shown 
to improve survival, and is not routinely indicated 
in FIGO stage I and II disease. However, it could be 
considered for selected high-risk cases.
4. Advanced/metastatic LMS and undifferentiated 
endometrial sarcoma are treated systemically with 
the same drugs as STS at other sites. There is retro-
spective evidence that ifosfamide may be less effec-
tive in leiomyosarcoma.
5. Advanced/metastatic ESS can be treated with oestro-
gen deprivation therapy, with an aromatase inhibitor 
or progestogen.
Retroperitoneal sarcomas
Although the principles of management of retroperito-
neal sarcomas are similar to those for extremity tumours, 
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there are some important differences. Surgical manage-
ment should be by surgeons specialised in the manage-
ment of retroperitoneal sarcoma who are members of the 
sarcoma MDT.
Contrast-enhanced CT of the chest, abdomen, and pel-
vis is used for staging and may be a valuable aid to diag-
nosis of well-differentiated/dedifferentiated liposarcoma, 
and in helping to plan surgery. In most cases biopsy will 
be required to confirm the diagnosis, although may be 
considered unnecessary if the radiological appearances 
are typical for retroperitoneal liposarcoma. The biopsy 
track should be planned to reduce any risk of tumour 
seeding or complications.
Complete primary macroscopic resection gives the best 
chance of long-term cure and so the importance of sur-
gical planning is paramount. Surgical margins are often 
more difficult to define as transcoelomic spread with 
distant contamination within the abdomen may occur. 
The goal of ‘wide excision’ is unlikely to be achievable in 
most cases. Here, the objective is “planned marginal exci-
sion”, achieving appropriate margins that balance tumour 
control with minimising operative morbidity and retain-
ing function. However, multi-visceral resection may be 
appropriate if necessary to permit “en bloc” resection of 
tumour, organs frequently sacrificed include kidney and 
spleen, and partial organ resection and vascular recon-
structions may occasionally be required. Pre-operative 
assessment of contralateral renal function should be 
considered. Resection of tumour leaving behind gross 
macroscopic disease is of limited benefit and may cause 
unnecessary morbidity. Studies have shown the impor-
tance of adherence to proper surgical guidelines in the 
management of this disease, with a direct impact on sur-
vival [134].
The role of pre or post-operative radiotherapy is less 
well defined, and although it may be of value in individual 
patients, it is not considered routine. It is often difficult 
to define the radiation volume and dose is limited due to 
the risk of small bowel and other organ toxicity. In cases 
where it is possible to define “high-risk margins” post-
operative radiotherapy to a dose of 45–50 in 1.8 Gy frac-
tions should be considered [135]. In certain situations, 
for example, low pelvic tumours, higher doses of radia-
tion may be given as normal tissue tolerance is greater. 
Pre-operative radiotherapy is increasingly becoming a 
preferred option as the treatment volume is smaller and 
better defined and the tumour acts as its own “spacer” 
[136]. Currently the STRASS trial, randomising patients 
with RPS to surgery or surgery plus pre-operative radio-
therapy, is recruiting patients [137].
There is currently no evidence to support the use of 
neo-adjuvant or adjuvant chemotherapy in the manage-
ment of retroperitoneal sarcomas, although as in other 
STS is may be considered in more sensitive histologies 
such as synovial sarcoma.
Routine CT scanning for asymptomatic relapse is con-
troversial due to the relative ineffectiveness of salvage 
surgery. However, surgery for local recurrence may be 
considered in cases where there has been a reasonable 
disease-free interval (over 12 months) particularly in low-
grade disease, or disease demonstrating a good response 
to systemic treatment.
Palliative chemotherapy should be considered for the 
same indications as limb sarcomas but well-differenti-
ated/de-differentiated liposarcoma is relatively chemore-
sistant. Options usually include doxorubicin, infusional 
ifosfamide, or trabectedin any of which might be con-
sidered in the first-line setting. Early data suggests that 
eribulin may have a role [117] although it has not yet 
been appraised by NICE.
For many patients with advanced disease, aggressive 
therapy may not be appropriate, and good symptomatic 
management, and palliative care support are required.
Key recommendations
1. Standard treatment is en bloc complete resection 
with macroscopically clear margins.
2. Treatments for relapse are relatively ineffective; 
symptomatic management and palliative support of 
the patient should be offered where appropriate.
Borderline tumours
This group of soft tissue tumours are not considered typi-
cal sarcomas. They tend to remain localised, and whilst 
local recurrence following surgery can occur, they do not 
generally metastasise.
Lipomas and atypical lipomatous tumours
The most common differential diagnosis seen by the sar-
coma MDT is that between lipoma and atypical lipoma-
tous tumours (ALT), also known as well-differentiated 
liposarcoma (WDL). Essentially ALT and WDL are syn-
onymous, as described in the WHO classification [10]. 
The latter term is more commonly applied to tumours 
in sites such as the retroperitoneum and mediastinum 
where surgical excision with a wide margin is unlikely, 
and therefore local recurrence almost inevitable; pro-
gressive dedifferentiation with each recurrence is often 
observed (see “Retroperitoneal sarcomas” section). ALT/
WDL of the extremities is distinct from lipoma in that it 
has the propensity for local recurrence, however dediffer-
entiation into a more aggressive disease is extremely rare.
Differentiating lipoma and ALT radiologically is not 
reliable but certain features seen on MRI can be help-
ful such as size and intratumoural septation [138, 139]. 
Histological and cytogenetic analysis of tumour allows 
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confirmation of diagnosis, although small pre-operative 
biopsies may be misleading [140, 141].
Surgical resection is the usual treatment for ALT, and 
the prognosis is usually excellent [142–144]. However, 
particularly in older patients, if surgery is likely to be 
morbid, or the patient has significant comorbidities then 
radiological surveillance can be considered. In larger 
tumours, or those where clear margins are difficult to 
achieve, adjuvant radiotherapy may very occasionally be 
considered [145].
Key recommendations
1. Atypical lipomatous tumours and well differentiated 
liposarcomas are essentially synonymous. Surgical 
resection with a clear margin is standard treatment 
and prognosis is usually excellent.
Desmoid‑type fibromatosis
Fibromatosis is a benign, clonal tumour, which although 
sometimes locally aggressive (even fatal on occasion), 
has not been reported to metastasise. Although usually 
sporadic it may occur in association with familial adeno-
matous polyposis (FAP), or Gardner syndrome caused by 
germline mutations in the APC gene. Cases of sporadic 
fibromatosis usually harbour mutations in CTNNB1, the 
gene for beta-catenin.
Diagnostic investigation follows the standard process 
for STS. The disease may occur at the sites of previous 
scars and can be related to hormonal changes in women, 
for example surrounding pregnancy. Pregnancy related 
fibromatosis tends to have a good outcome and progres-
sion during pregnancy is common but manageable. It is not 
generally a contraindication to future pregnancy [146]. In 
cases where a link to FAP may be more likely (e.g. young 
male, abdominal disease, CTNNB1 mutation negative) then 
it is important to exclude a family history of bowel can-
cer, and it may be appropriate to screen for germline APC 
mutations or consider investigations such as colonoscopy.
The natural history of the disease is unpredictable and 
optimal management is not fully established, although a 
European Consensus has recently been published and pro-
vides useful guidance [147]. Following initial diagnosis, the 
tumour may continue to grow, stabilise, or even regress 
spontaneously [148]. The 5-year progression-free survival 
may be up to 50%. In addition, surgical resection even with 
apparently clear margins results in relatively high rates of 
local recurrence in up to half of cases. Increasingly, watch-
ful waiting is considered the standard first-line option. 
Interval review with MRI scans is recommended and treat-
ment initiated on significant disease progression.
Standard treatment in cases where surveillance is not 
selected, or progression has occurred, is complete sur-
gical excision. Unlike the general situation with STS the 
finding of positive margins is less closely related to risk 
of relapse; long-term remission may be seen despite posi-
tive margins, and conversely relapse is not uncommon in 
clearly resected disease. The exception to this is fibroma-
tosis arising in the abdominal wall of young females, 
where relapse rates following surgery are low; in one 
series under 10% at 5 years [149].
Radiotherapy may be effective treatment for patients 
with unresectable tumours or may be given as adju-
vant therapy following surgery for recurrent disease, 
especially if further surgery would result in significant 
morbidity and functional deficit. A dose of 50–56 Gy is 
usually employed [150, 151].
Systemic treatment is recommended in selected cases 
with unresectable disease and is another option following 
progression during watchful waiting. Hormone therapies 
such as tamoxifen have been reported to be beneficial 
but, because of the unpredictable natural history of this 
disease, their true value remains unproven due to the 
lack of appropriate clinical trial data. Nonsteroidal anti-
inflammatory drugs (NSAIDs) have been reported to 
improve the response to tamoxifen. The precise choice of 
NSAID is uncertain and although selective COX2 inhibi-
tors have been used, the evidence that they are superior 
is lacking. NSAIDS have an impact on the beta-catenin 
signalling pathway.
Chemotherapy is usually reserved for patients with sig-
nificant symptoms who have failed to respond to more 
benign interventions such as the use of NSAIDs and 
tamoxifen. Weekly administration of methotrexate and 
vinblastine or vinorelbine has reasonable activity and is 
generally well tolerated. More recently pegylated liposo-
mal doxorubicin (Caelyx) has been reported to have sig-
nificant activity with acceptable toxicity, and currently 
is considered treatment of choice by many investigators 
[152]. Targeted therapies such as imatinib and pazopanib 
have also been investigated, and both objective remis-
sions and disease stabilisation have been reported [114, 
153, 154]. Another option for limb tumours is isolated 
limb perfusion (ILP) with tumour necrosis factor alpha 
and melphalan.
Key recommendations
1. A diagnosis of familial adenomatous polyposis (FAP) 
needs to be considered in some fibromatosis cases.
2. Initial standard treatment for fibromatosis is watchful 
waiting.
3. Systemic treatments such as tamoxifen, NSAIDS or 
chemotherapy may be used definitively, or neoadju-
vantly before surgery.
4. Surgery can be considered if progression occurs.
5. Radiotherapy can be used in the adjuvant setting, or 
for inoperable disease.
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Peripheral nerve tumours
Peripheral nerve tumours are often referred to, or man-
aged by, sarcoma services, and include several subtypes 
including neurofibromas, schwannomas, and malignant 
peripheral nerve sheath tumours (MPNST). They may 
be benign or malignant, and sporadic, or in a significant 
minority of cases, associated with the genetic conditions 
neurofibromatosis type 1 or 2. The latter conditions will 
not be discussed in detail in this guideline but overall 
management is likely to be in collaboration with regional 
genetic medicine or specialist neurofibromatosis services.
Presentation may be as a mass, but pain, or focal neu-
rological symptoms may also be a feature. Rapid pro-
gression of symptoms or signs may indicate a higher 
likelihood of malignancy [155]. Ultrasound, and in par-
ticular MRI scans can suggest the diagnosis with fea-
tures such as direct continuity with a nerve or location 
along a typical nerve distribution [156]. PET-CT may 
assist in differentiating benign from malignant tumours 
[32, 33].
In many cases a biopsy will be appropriate to con-
firm the diagnosis. However, this can be painful for the 
patient, or rarely associated with neurological injury. 
Therefore, some lesions with characteristic appearances 
on MRI scan may be considered for excision biopsy 
under general anaesthetic. Expert pathological assess-
ment will be required as nerve tumours can be diagnosti-
cally challenging [157].
Treatment is usually surgical resection, although in 
some cases management can be conservative with obser-
vation alone. Surveillance may be considered in asymp-
tomatic schwannomas, or other neural tumours with no 
malignant features [158]. For benign tumours resection 
with minimisation of residual neurological deficit is the 
aim, and in many cases can result in improvement in 
peripheral nerve function [159]. Malignant peripheral 
nerve sheath tumours (MPNST) are aggressive tumours 
with a relatively poor prognosis [160]. In general man-
agement is as for malignant soft-tissue sarcomas as 
described earlier in this guideline.
Key recommendations
1. In the presence of a peripheral nerve tumour a diag-
nosis of neurofibromatosis should be considered.
2. Treatment is usually surgical excision although sur-
veillance can be considered in clearly benign cases.
3. Malignant peripheral nerve sheath tumours are 
aggressive malignancies treated in the same way as 
other high-grade sarcomas.
Dermatofibrosarcoma protuberans (DFSP)
DFSP is a rare neoplasm of the dermal layer of the skin. 
This is best considered a borderline malignancy that 
rarely metastasises but is locally aggressive, may produce 
significant morbidity, and occasionally proves fatal. Local 
recurrence following surgery is common and wide exci-
sion is essential except in situations where wide excision 
would result in significant morbidity or functional loss. 
In this instance, Mohs surgery can provide an alternative 
to initial wide excision and may be delivered through col-
laboration with a skin cancer MDT.
Radiotherapy should be considered for inoperable 
disease, and can result in durable remissions. Adjuvant 
radiotherapy may also be used if the margins are involved 
and re-excision is not possible [161].
Systemic treatment is appropriate in selected cases 
with unresectable or metastatic disease. DFSP is driven 
by a t(17;22) translocation that results in over-expression 
of platelet derived growth factor beta (PDGFβ). There-
fore, the PDGFβ receptor may be inhibited by imatinib, 
which is licensed for the treatment of unresectable DFSP 
[162].The challenges with using targeted agents such as 
this for benign conditions are balancing the toxicity with 
benefit, the financial cost, and also defining an appropri-
ate end-point, and optimum duration of treatment.
Key recommendations
1. Treatment of DFSP is wide surgical excision, Mohs 
surgery may be appropriate in selected cases to 
reduce functional loss.
2. Adjuvant radiotherapy may be considered if surgical 
resection is incomplete, and re-excision not possible.
3. Imatinib may provide an option for neo-adjuvant 
treatment in borderline resectable disease, or effec-
tive palliation for patients with unresectable DFSP.
Atypical fibroxanthoma (AFX)
AFX is a low-grade cutaneous spindle cell tumour con-
sidered a superficial variant of malignant fibrous his-
tiocytoma (MFH). It may be mistaken clinically or 
histologically for other spindle cell tumours. It is usually 
cured by surgical excision although local recurrence is 
fairly common and metastases are seen in less than 1% 
of cases. AFX greater than 2  cm in size and with other 
adverse pathological features may be regarded as pleo-
morphic dermal sarcomas [163]; they appear to share 
similar oncogene expression and mutations [164].
Key recommendation
1. AFX is usually cured by surgical excision, although 
larger tumours with adverse pathological features 
may be regarded as pleomorphic dermal sarcomas.
Tenosynovial giant cell tumour (TGCT)
This family of benign neoplastic conditions presents as two 
forms, reclassified by the WHO in 2013 [10], as either a 
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single nodule (localised, L-TGCT; previously GCT of ten-
don sheath or nodular tenosynovitis) or multiple nodules 
(diffuse-type, D-TGCT; previously pigmented villonodu-
lar synovitis, PVNS), generally affecting the synovium in 
young adults. It is usually treated by surgery alone but local 
relapses can occur [165]. Arthroscopic or open synovec-
tomy may have a role in diffuse disease. In nodular intra-
articular disease, the aim is complete removal, and doing 
this without morsellisation may be advantageous.
The role of radiotherapy is unclear but may be consid-
ered for symptomatic residual or recurrent disease when 
further excision is not possible. Yttrium synovectomy has 
been used in the adjuvant setting in diffuse intraarticular 
disease [166]. Due to a translocation involving the mac-
rophage colony-stimulating factor (M-CSF or CSF1) gene 
seen in a proportion of cells, imatinib has demonstrated 
activity in its treatment [167]. It may be considered for a 
3-month course prior to surgery in borderline operable 
cases, although will require approval for funding. Its use in 
the palliative setting can also be considered although the 
treatment endpoints and duration are not clear [168]. New 
targeted drugs are currently undergoing investigation.
Key recommendation
1. Tenosynovial giant cell tumour is generally treated 
by surgery alone, although rarely radiotherapy or 
imatinib may have a role.
Inflammatory myofibroblastic tumour (IMT)
IMT is a neoplasm consisting of a spindle-cell prolif-
eration and inflammatory infiltrate. It most commonly 
occurs in the lungs but can be seen in the abdomen and 
pelvis or maxillofacial region. Treatment is usually surgi-
cal excision although local recurrences and very rarely 
metastases can occur. It may respond to steroids, but in 
around 50% of cases rearrangements in the ALK locus on 
chromosome 2p23 have been detected. In these cases, 
treatment with an ALK targeting drug such as crizotinib 
may be useful [169] and is currently being investigated in 
the CREATE study [170].
Key recommendation
1. Inflammatory myofibroblastic tumour is treated with 




1. Any patient with a soft tissue mass that is increasing 
in size, or has a size more than 5 cm, whether or not 
it is painful, should either be referred for an urgent 
ultrasound scan, or referred directly to a sarcoma 
diagnostic centre.
2. If the ultrasound scan does not definitely confirm 
benign pathology, then the patient should be referred 
for further investigation on an urgent suspected can-
cer referral pathway.
3. Any retroperitoneal or intra-abdominal mass with 
imaging appearances suggestive of a soft tissue sar-
coma should be referred to a specialist centre before 
biopsy or surgical treatment.
Referral and assessment
1. All patients with a suspected STS should be man-
aged by a specialist Sarcoma MDT as specified in the 
NICE guidance.
2. Ultrasound scan by a musculoskeletal radiologist 
should be considered as the first-line investigation, 
and may be supplemented by ultrasound-guided core 
biopsy.
3. Magnetic resonance imaging and core needle biopsy 
are recommended prior to definitive surgery.
4. Imaging of the thorax by CT scan for lung metastases 
should be done prior to radical treatment. Further 
staging may be considered depending on subtype and 
location of the sarcoma.
Management of localised disease
 1. Surgery is the standard treatment for most patients 
with localised STS.
 2. For those patients with resectable disease, a wide 
excision through normal uninvolved tissues is the 
surgical procedure of choice.
 3. Defining a “wide” margin is controversial, but with 
the addition of effective adjuvant therapy (e.g. radio-
therapy) a tumour free margin (R0) may be adequate.
 4. Where a wide excision is not possible due to ana-
tomical constraints, a planned marginal or micro-
scopically positive margin against a critical structure, 
plus radiotherapy, for intermediate and high grade 
tumours, may be an appropriate means of achieving 
tumour control while maintaining physical function.
 5. Occasionally amputation should be undertaken as 
the only surgical option to achieve adequate mar-
gins.
 6. For patients with borderline resectable tumours, pre-
operative treatment with chemotherapy and/or radi-
otherapy should be considered depending on histol-
ogy.
 7. Pre- or post-operative radiotherapy is recommended 
along with surgical resection of the primary tumour 
for the majority of patients with high-grade tumours, 
and for selected patients with large or marginally 
excised, low-grade tumours.
 8. The recommended dose for post-operative radio-
therapy is 60–66 Gy.
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 9. Pre-operative radiotherapy is advantageous in terms 
of better long-term functional outcome, with equiv-
alent rates of disease control, when compared with 
post-operative radiotherapy. There is however an 
increased risk of acute post-operative wound com-
plications.
 10. The recommended dose for pre-operative radiother-
apy is 50 Gy.
 11. Adjuvant chemotherapy is not routinely recom-
mended but could be considered in situations where 
achieving local control is likely to be compromised, 
or the risk of metastatic disease is particularly high, 
with a lower threshold for its use in the more che-
mosensitive sarcoma subtypes.
Prognosis and follow‑up for primary disease
1. It is recommended that patients with intermedi-
ate or high-grade sarcoma are followed up every 
3–4 months for the first 2–3 years, then twice a year 
for up to 5 years, and annually thereafter for a total of 
8–10 years.
2. Patients with low-grade sarcoma should be followed 
up every 4–6 months for 3–5 years, then annually.
3. Standard follow-up practice should consist of:
a. Review of any new symptoms reported by the 
patient,
b. Clinical examination to focus on local recur-
rence, with imaging follow-up where indicated 
by clinical suspicion,
c. Routine chest X-ray to exclude pulmonary 
metastases.
d. Monitoring for late-effects of treatment.
4. New models of follow-up warrant further investiga-
tion.
Prognosis and treatment of advanced disease
1. Systemic treatments (SACT) for the majority of 
advanced STS are not curative; median survival time 
is 12–18 months. Published chemotherapy response 
rates vary enormously; from 10–50% depending on 
the drugs used, patient selection, and tumour grade 
and histological subtype.
2. Treatment recommendations should be guided by 
patient performance status, disease extent, rate of 
progression, and potential sensitivity to treatment.
3. Standard first-line treatment is single-agent doxoru-
bicin.
4. Ifosfamide may be used first-line if anthracyclines are 
contraindicated, and is a standard option for second-
line therapy.
5. Although the combination of doxorubicin and ifosfa-
mide has not been demonstrated to improve survival 
in comparison to single agent doxorubicin first-line, 
response rates are higher and it may be considered in 
individual patients where a response would improve 
symptoms or facilitate other treatment modalities.
6. Additional second-line agents include trabectedin, 
and the combination of gemcitabine and docetaxel. 
The choice of agent depends on histology, toxicity 
profile and patient preference.
7. A number of other agents such as dacarbazine and 
pazopanib can be considered beyond second-line 
depending on patient fitness and funding con-
straints.
8. Surgical resection of locally recurrent disease should 
be considered where feasible. For patients with oli-
gometastatic disease surgery, radiotherapy, or abla-
tive therapies (RFA, SABR, cryotherapy, microwave, 
ECT) should be considered in individual cases, 
although there are limited data on survival benefit.
Uterine sarcomas
1. Standard treatment for all localised uterine sarcomas 
is TAH. Lymphadenectomy is not routinely indicated.
2. Total abdominal hysterectomy with bilateral oopho-
rectomy is indicated for endometrial stromal sarcoma. 
These patients should not have post-operative hor-
mone replacement therapy and tamoxifen is contrain-
dicated. Use of adjuvant oestrogen deprivation therapy 
is not routinely indicated.
3. Adjuvant pelvic radiotherapy has not been shown to 
improve survival, and is not routinely indicated in 
FIGO stage I and II disease. However, it could be con-
sidered for selected high-risk cases.
4. Advanced/metastatic LMS and undifferentiated endo-
metrial sarcoma are treated systemically with the same 
drugs as STS at other sites. There is retrospective evi-
dence that ifosfamide may be less effective in leiomyo-
sarcoma.
5. Advanced/metastatic ESS can be treated with oestro-
gen deprivation therapy, with an aromatase inhibitor 
or progestogen.
Retroperitoneal sarcomas
1. Standard treatment is en bloc complete resection 
with macroscopically clear margins.
2. Treatments for relapse are relatively ineffective; 
symptomatic management and palliative support of 
the patient should be offered where appropriate.
Lipomas and atypical lipomatous tumours
1. Atypical lipomatous tumours and well differentiated 
liposarcomas are essentially synonymous. Surgical 
resection with a clear margin is standard treatment 
and prognosis is usually excellent.
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Desmoid‑type fibromatosis
1. A diagnosis of familial adenomatous polyposis (FAP) 
needs to be considered in some fibromatosis cases.
2. Initial standard treatment for fibromatosis is watchful 
waiting.
3. Systemic treatments such as tamoxifen, NSAIDS or 
chemotherapy may be used definitively, or neoadaju-
vantly before surgery for fibromatosis.
4. Surgery can be considered for fibromatosis if pro-
gression occurs.
5. Radiotherapy can be used in the adjuvant setting, or 
for inoperable fibromatosis.
Peripheral nerve tumours
1. In the presence of a peripheral nerve tumour a diag-
nosis of neurofibromatosis should be considered.
2. Treatment of peripheral nerve tumours is usually 
surgical excision although surveillance can be consid-
ered in clearly benign cases.
3. Malignant peripheral nerve sheath tumours are 
aggressive malignancies treated in the same way as 
other high-grade sarcomas.
Dermatofibrosarcoma protruberans (DFSP)
1. Treatment of DFSP is wide surgical excision, Mohs 
surgery may be appropriate in selected cases to 
reduce functional loss.
2. Adjuvant radiotherapy may be considered for DFSP if 
surgical resection is incomplete, and re-excision not 
possible.
3. Imatinib may provide an option for neo-adjuvant 
treatment in borderline resectable disease, or effec-
tive palliation for patients with unresectable DFSP.
Atypical fibroxanthoma (AFX)
1. AFX is usually cured by surgical excision, although 
larger tumours with adverse pathological features 
may be regarded as pleomorphic dermal sarcomas.
Tenosynovial giant cell tumour (TGCT)
1. Tenosynovial giant cell tumour is generally treated 
by surgery alone, although rarely radiotherapy or 
imatinib may have a role.
Inflammatory myofibroblastic tumour (IMT)
1. Inflammatory myofibroblastic tumour is treated with 
surgery, although may be responsive to steroids or 
crizotinib.
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